AstraZeneca Acquires Modella AI To Scale Multimodal AI And Agents Across Oncology R&D

来源：Pulse | 发布时间：2026-03-31

摘要：阿斯利康收购波士顿肿瘤 AI 初创公司 Modella AI（2025 年 7 月合作升级），未披露财务细节。其将整合对方生成式 AI、智能体 AI 工具至肿瘤研发体系，聚焦临床试验加速、生物标志物发现与患者分层优化，解决肿瘤药研发因患者选择不当的失败痛点。此举标志药企从 AI 合作试点转向平台自主化，凸显生物标志物为医药 AI 研发核心方向，也将加剧行业 AI 研发竞争。

Pharmaceutical giant AstraZeneca made a big splash at a healthcare conference: acquiring Modella AI, an AI startup focused on oncology, and fully integrating its generative AI and agentic AI tools into its own oncology R&D system. This wasn’t a spur-of-the-moment decision—back in July 2025, the two parties had already started collaborating, and the “superpowers” demonstrated by AI in clinical trials prompted the pharmaceutical company to upgrade the partnership decisively.

In the past, anti-cancer drug R&D often stumbled over “finding the wrong patients”: promising new drugs failed in late-stage trials simply because the precise target population wasn’t identified. Modella AI’s specialty is quickly identifying “biomarkers” that predict treatment efficacy from massive amounts of pathological images and genomic data—acting like a navigator to find the “right audience” for drugs. Now that AstraZeneca has brought this “smart hunter” in-house, it can not only accelerate clinical trial progress but also increase the approval rate of targeted therapies. This move has also set a new industry trend: large pharmaceutical companies are no longer content with collaborating with AI firms but are directly “buying out” core technologies to seize the high ground in precision medicine.

药企豪掷千金收 AI，生物标志物成 “终极猎物”

全球制药巨头阿斯利康（AstraZeneca）在医疗健康大会上抛出重磅消息：收购专注肿瘤领域的 AI 初创公司 Modella AI，把对方的生成式 AI 和智能体 AI 工具全盘纳入自家肿瘤研发体系。这可不是一时兴起 —— 早在 2025 年 7 月，两家就已经开始合作，AI 在临床试验中展现的 “超能力” 让药企果断升级合作模式。

过去抗癌药研发常栽在 “找错患者” 上：明明是潜力新药，却因为没找到精准适用人群而在后期试验中失败。Modella AI 的拿手好戏就是从海量病理图像和基因组数据中，快速揪出能预测疗效的 “生物标志物”，相当于给药物找对 “目标人群” 的导航仪。现在阿斯利康把这台 “智能猎手” 收归麾下，不仅能加速临床试验进程，还能提高靶向疗法的获批概率。这波操作也掀起了行业新风向：大型药企不再满足于和 AI 公司合作，而是直接 “买断” 核心技术，抢占精准医疗的制高点～